Primobolan 200 200mg/ml 10ml Vial by Dragon-Pharma

Usage

1. Verify the batch HPLC certificate and LAL endotoxin report for your specific Dragon-Pharma Primobolan 200 vial lot before the first use — batch numbers are printed on the vial label.
2. Warm the 10 ml vial to room temperature (20–25 °C) by holding it in your palm for 60–90 seconds; this reduces oil viscosity at the 200 mg/ml concentration and allows smoother draw.
3. Draw the calculated dose using a 21–23 gauge needle into a 2–3 ml syringe; for a 200 mg dose at 200 mg/ml, draw exactly 1.0 ml and confirm the volume against the syringe graduation.
4. Swap to a fresh 23–25 gauge injection needle (1–1.5 inch length for intramuscular depth) before administration; this preserves needle sharpness and minimises injection-site trauma.
5. Inject intramuscularly into the gluteal, lateral quadriceps, or deltoid site using a slow, steady plunger press appropriate to oil-based injectables; aspirate briefly before injecting to confirm extra-vascular placement.
6. Following injection, re-seal the vial septum with a clean cap, document the date of first use, and store upright in a cool, dark location — the multi-dose 10 ml format is designed for repeated sterile withdrawal over the full cycle duration.

Warnings

Frequently asked questions

What is the pharmacological difference between Methenolone Enanthate and Methenolone Acetate in injectable form?

Methenolone Enanthate uses a C-7 acyl chain that forms a slow-releasing intramuscular depot, supporting twice-weekly injections. Methenolone Acetate in its older injectable form used a C-2 acyl chain, requiring daily administration due to rapid ester cleavage. The enanthate ester's longer carbon chain slows enzymatic hydrolysis, extending the active drug window by several days compared to the acetate.

Why does 200mg/ml Methenolone Enanthate require fewer millilitres per injection than 100mg/ml versions?

At 200 mg/ml, each millilitre contains twice the active compound of a 100 mg/ml formulation. A 200 mg dose at 200 mg/ml requires only 1 ml of oil, whereas the same dose at 100 mg/ml requires 2 ml. Reducing per-injection oil volume directly lowers intramuscular depot pressure, decreasing post-injection site soreness — a clinically relevant advantage for twice-weekly administration schedules.

How does injecting Methenolone Enanthate compare to taking oral Methenolone Acetate tablets for bioavailability?

Injectable Methenolone Enanthate bypasses hepatic first-pass metabolism entirely, delivering near-complete systemic bioavailability of the liberated hormone. Oral Methenolone Acetate undergoes first-pass processing in the liver, reducing effective bioavailability to an estimated 62–72 %. For equal systemic exposure, oral doses must be higher than injectable doses — making the injectable enanthate form more dose-efficient per milligram administered.

How should a 10 ml vial of Dragon-Pharma Primobolan 200 be stored after the first use?

After initial puncture, store the 10 ml multi-dose vial at 15–25 °C in a dark, dry location away from direct sunlight or moisture. Refrigeration is not required but is acceptable; if refrigerated, allow the vial to reach room temperature before drawing to reduce oil viscosity. Use a fresh sterile needle for each withdrawal to maintain septum integrity, and discard the vial if particulate matter, cloudiness, or discolouration is observed.

Can an insulin syringe be used to draw and inject Dragon-Pharma Primobolan 200 at 200mg/ml?

Insulin syringes (typically 0.5–1 ml, 28–31 gauge) are not recommended for Primobolan 200 at 200 mg/ml. The high oil viscosity at this concentration resists flow through insulin-gauge needles, making accurate draw and full ejection difficult. A 21–23 gauge draw needle and a 23–25 gauge 1–1.5 inch injection needle in a 2–3 ml syringe is the practical standard for smooth administration of this concentration. (2) angle_used

Manufacturer

Dragon-Pharma's formulation innovation programme is most visible in its concentration engineering decisions — and Primobolan 200 at 200 mg/ml represents the clearest example of this philosophy applied to Methenolone Enanthate. Reaching a stable, homogeneous 200 mg/ml oil suspension requires specific excipient balancing: the ratios of benzyl benzoate (solubilising agent) and benzyl alcohol (preservative/co-solvent) must be recalculated relative to those used in standard 100 mg/ml formulations to prevent precipitation, maintain injectability, and preserve sterility across the full 10 ml multi-dose format. Dragon-Pharma's formulation development team validates each new concentration variant through accelerated stability testing — exposing finished vials to temperature-cycling conditions before release to confirm that no API crystallisation or excipient phase separation occurs over the product's declared shelf life. The Methenolone Enanthate API used in Primobolan 200 is identity-confirmed by in-house high-performance liquid chromatography (HPLC) at both the incoming raw material stage and again in the finished injectable, generating two independent potency data points per batch. A Limulus Amebocyte Lysate (LAL) endotoxin assay applied to the finished product verifies that bacterial endotoxin levels fall within the injectable specification before the batch is cleared for distribution. This two-stage, two-analyte release protocol is what allows Dragon-Pharma to offer a double-density Methenolone product with the same analytical confidence that underpins the rest of its injectable line.